Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02125461

NCT02125461
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You must be at least 18 years old
  • You must have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is at an advanced stage (Stage III) and cannot be removed by surgery
  • You must have already received at least 2 cycles of a chemotherapy treatment containing platinum, given at the same time as radiation therapy
  • You must be in generally good health and able to carry out daily activities with little or no difficulty (confirm with trial site)
  • Your doctor must estimate that you are expected to live for more than 12 weeks

Who may not be able to join:

  • You have previously been treated with certain types of immunotherapy drugs known as anti-PD-1 or anti-PD-L1 antibodies
  • You have, or have had in the past, a condition where your immune system attacks your own body, or a condition that weakens your immune system
  • You have serious or uncontrolled health conditions, including active bleeding problems, or active infections such as Hepatitis B, Hepatitis C, or HIV
  • You have uncontrolled conditions such as heart failure with symptoms, very high blood pressure that cannot be managed, or chest pain caused by reduced blood flow to the heart
  • You are still experiencing side effects from your previous chemotherapy and radiation treatment that are more than mild in severity (confirm with trial site)
  • You have, or have had in the past, an inflammatory bowel disease such as Crohn's disease or ulcerative colitis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
7 May 2014
Est. completion
13 February 2017

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇨🇱 Chile 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇳🇱 Netherlands 🇵🇪 Peru 🇵🇱 Poland 🇸🇬 Singapore 🇸🇰 Slovakia 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇹🇭 Thailand Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States 🇻🇳 Vietnam

13 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov